FZD10-targeted α-radioimmunotherapy with ²²⁵ Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model.

ABSTRACT: Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1 trial of β-radioimmunotherapy (RIT) with the ⁹⁰ Y-labeled anti-FZD10 antibody OTSA101 revealed a need for improved efficacy. The present study evaluated the potential of α-RIT with OTSA101 labeled with the α-emitter ²²⁵ Ac. Competitive inhibition and cell binding assays showed that specific binding of ²²⁵ Ac-labeled OTSA101 to SYO-1 synovial sarcoma cells was comparable to that of the imaging agent ¹¹¹ In-labeled OTSA101. Biodistribution studies showed

SUBMITTER: Sudo H 

PROVIDER: S-EPMC8819345 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature